Post-ERCP Pancreatitis: Prevention, Diagnosis and Management
Endoscopic retrograde cholangiopancreatography (ERCP) carries a post-ERCP pancreatitis (PEP) rate of 2–10%, which could be as high as 30–50% in high-risk cases. PEP is severe in up to 5% of cases, with potential for life-threatening complications, including multi-organ failure, peripancreatic fluid...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-09-01
|
| Series: | Medicina |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1648-9144/58/9/1261 |
| _version_ | 1797485033019146240 |
|---|---|
| author | Oscar Cahyadi Nadeem Tehami Enrique de-Madaria Keith Siau |
| author_facet | Oscar Cahyadi Nadeem Tehami Enrique de-Madaria Keith Siau |
| author_sort | Oscar Cahyadi |
| collection | DOAJ |
| description | Endoscopic retrograde cholangiopancreatography (ERCP) carries a post-ERCP pancreatitis (PEP) rate of 2–10%, which could be as high as 30–50% in high-risk cases. PEP is severe in up to 5% of cases, with potential for life-threatening complications, including multi-organ failure, peripancreatic fluid collections, and death in up to 1% of cases. The risk of PEP is potentially predictable and may be modified with pharmacological measures and endoscopist technique. This review covers the definition, epidemiology and risk factors for PEP, with a focus on the latest evidence-based medical and endoscopic strategies to prevent and manage PEP. |
| first_indexed | 2024-03-09T23:13:57Z |
| format | Article |
| id | doaj.art-bab34eef5a2c41ada544e365c245c918 |
| institution | Directory Open Access Journal |
| issn | 1010-660X 1648-9144 |
| language | English |
| last_indexed | 2024-03-09T23:13:57Z |
| publishDate | 2022-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Medicina |
| spelling | doaj.art-bab34eef5a2c41ada544e365c245c9182023-11-23T17:40:38ZengMDPI AGMedicina1010-660X1648-91442022-09-01589126110.3390/medicina58091261Post-ERCP Pancreatitis: Prevention, Diagnosis and ManagementOscar Cahyadi0Nadeem Tehami1Enrique de-Madaria2Keith Siau3St. Josef-Hospital, A Hospital of the Ruhr-University Bochum, 44791 Bochum, GermanyDepartment of Gastroenterology, University Hospital Southampton NHS Foundation Trust, Southampton SO16 6YD, UKDepartment of Gastroenterology, Dr. Balmis General University Hospital and Department of Clinical Medicine, Miguel Hernández University, 03010 Alicante, SpainDepartment of Gastroenterology, Royal Cornwall Hospitals NHS Trust, Truro TR1 3LJ, UKEndoscopic retrograde cholangiopancreatography (ERCP) carries a post-ERCP pancreatitis (PEP) rate of 2–10%, which could be as high as 30–50% in high-risk cases. PEP is severe in up to 5% of cases, with potential for life-threatening complications, including multi-organ failure, peripancreatic fluid collections, and death in up to 1% of cases. The risk of PEP is potentially predictable and may be modified with pharmacological measures and endoscopist technique. This review covers the definition, epidemiology and risk factors for PEP, with a focus on the latest evidence-based medical and endoscopic strategies to prevent and manage PEP.https://www.mdpi.com/1648-9144/58/9/1261post-ERCP pancreatitisERCPpancreatic stentingnon-steroidal anti-inflammatory drugs |
| spellingShingle | Oscar Cahyadi Nadeem Tehami Enrique de-Madaria Keith Siau Post-ERCP Pancreatitis: Prevention, Diagnosis and Management Medicina post-ERCP pancreatitis ERCP pancreatic stenting non-steroidal anti-inflammatory drugs |
| title | Post-ERCP Pancreatitis: Prevention, Diagnosis and Management |
| title_full | Post-ERCP Pancreatitis: Prevention, Diagnosis and Management |
| title_fullStr | Post-ERCP Pancreatitis: Prevention, Diagnosis and Management |
| title_full_unstemmed | Post-ERCP Pancreatitis: Prevention, Diagnosis and Management |
| title_short | Post-ERCP Pancreatitis: Prevention, Diagnosis and Management |
| title_sort | post ercp pancreatitis prevention diagnosis and management |
| topic | post-ERCP pancreatitis ERCP pancreatic stenting non-steroidal anti-inflammatory drugs |
| url | https://www.mdpi.com/1648-9144/58/9/1261 |
| work_keys_str_mv | AT oscarcahyadi postercppancreatitispreventiondiagnosisandmanagement AT nadeemtehami postercppancreatitispreventiondiagnosisandmanagement AT enriquedemadaria postercppancreatitispreventiondiagnosisandmanagement AT keithsiau postercppancreatitispreventiondiagnosisandmanagement |